Activity of 2-Aryl-2-(3-indolyl)acetohydroxamates Against Drug-Resistant Cancer Cells
Many types of tumor, including glioma, melanoma, non-small cell lung, esophageal, head and neck cancer, among others, are intrinsically resistant to apoptosis induction and poorly responsive to current therapies with proapoptotic agents. In addition, tumors often develop multi-drug resistance based on the cellular efflux of chemotherapeutic agents. Thus, novel anticancer agents capable of overcoming these intrinsic or developed tumor resistance mechanisms are urgently needed. We describe a series of 2-aryl-2-(3-indolyl)acetohydroxamic acids, which are active against apoptosis- and multidrug-resistant cancer cells as well as glioblastoma neurosphere stem-like cell cultures derived from patients. Thus, the described compounds serve as a novel chemical scaffold for the development of potentially highly effective clinical cancer drugs.
Introduction<!>Chemistry<!>(a) SAR analyses<!>(b) Activity against cells exhibiting various types of resistance to proapoptotic stimuli<!>(c) Quantitative videomicroscopy<!>(d) Redifferentiation of U87 cells to an astrocytic phenotype<!>(e) Activity against MDR cells, glioblastoma neurosphere stem-like cell cultures derived from patients and normal fibroblasts<!>Conclusion<!>General Experimental<!>Compound 1abf<!>Compound 1caf<!>Compound 1daf<!>Compound 1eaf<!>Preparation of 2-aryl-2-(3-indolyl)acetohydroxamates 3. General Method A<!>Preparation of 2-aryl-2-(3-indolyl)acetohydroxamates 3. General Method B<!>Compound 3aaaa<!>Compound 3aaab<!>Compound 3aaba<!>Compound 3aaca<!>Compound 3aada<!>Compound 3aaea<!>Compound 3aafa<!>Compound 3abfa<!>Compound 3acfa<!>Compound 3bafc<!>Compound 3bafa<!>Compound 3bafd<!>Compound 3aafe<!>Compound 3aaff<!>Compound 3aafg<!>Compound 3aafh<!>Compound 3aafi<!>Compound 3aafc<!>Compound 3aafj<!>Compound 3aafk<!>Compound 3aafd<!>Compound 3aafl<!>Compound 3aafm<!>Compound 3aafn<!>Compound 3aafo<!>Compound 3aafp<!>Compound 3cafa<!>Compound 3dafa<!>Compound 3cafe<!>Compound 3eafa<!>Synthesis of compound 6<!>Synthesis of compound 7<!>Cell culture<!>Antiproliferative Properties<!>Selection of Doxorubicin Resistant Cells<!>Quantitative videomicroscopy<!>Redifferentiation of malignant U87 cells to an astrocytic phenotype<!>LogP calculations
<p>Apoptosis-resistant cancers represent a major challenge in the clinic as most of the currently available chemotherapeutic agents work through the induction of apoptosis and, therefore, provide limited therapeutic benefits for the patients affected by these malignancies.1,2 Cancers with such intrinsic resistance to proapoptotic stimuli include the tumors of the lung, liver, stomach, esophagus, pancreas as well as melanomas and gliomas.3 For example, patients afflicted by a type of gliomas, known as glioblastoma multiforme,4,5 have a median survival expectancy of less than 14 months when treated with a standard protocol of surgical resection, radiotherapy and chemotherapy with temozolomide, carmustine or cisplatin.6 Because glioma cells display resistance to apoptosis, they respond poorly to such conventional chemotherapy with proapoptotic agents.5,7</p><p>Resistance to apoptosis is also an intrinsic property of tumor metastases. Successful treatment of metastases remains an important clinical challenge as 90% of cancer patients die from metastastic cancer spread.8 By acquiring resistance to anoikis, a cell death process resulting from the loss of contact with extracellular matrix or neighboring cells,8 metastatic cells display poor sensitivity to apoptosis induction and are thus poorly responsive to conventional proapoptotic chemotherapeutic agents.5,9,10 One solution to apoptosis resistance entails the complementation of cytotoxic therapeutic regimens with cytostatic agents and thus a search for novel cytostatic anticancer drugs that can overcome cancer cell resistance to apoptosis is an important pursuit.12–15</p><p>Often, tumors are initially susceptible to cancer agents and patients respond to chemotherapy but eventually experience a relapse in spite of the continuing treatment. In such instances of acquired resistance tumors generally become refractory to a broad spectrum of structurally and mechanistically diverse antitumor agents and this phenomenon is referred to as multidrug resistance (MDR).16,17 MDR usually results from upregulation of certain protein pumps, such as P-glycoprotein (P-gp) in cancer cells, causing a decreased intracellular drug concentration. MDR is a major factor that contributes to the failure of chemotherapy, for example with such widely used anticancer drugs as the vinca alkaloids18 or the taxanes.19</p><p>Our recent studies of a reaction of indole derivatives with β-nitrostyrenes in polyphosphoric acid (PPA)20 led to the discovery of an efficient synthesis of 2-aryl-2-(3-indolyl)acetohydroxamates. Although 2,2-diarylacetohydroxamates had been previously synthesized and studied as HDAC inhibitors,21,22 compounds in which one of the two aromatic rings is an indole moiety had not been reported in the literature. Thus, 2-aryl-2-(3-indolyl)acetohydroxamate was revealed to be a new chemotype prompting our thorough investigation of biological properties of compounds incorporating this structural feature. Although HDAC inhibition was not observed with these compounds (data not shown), these studies led to the discovery of significant activity associated with a number of synthesized compounds against cancer cell lines displaying resistance to various types of proapoptotic stimuli as well as glioblastoma neurosphere stem-like cell cultures derived from patients. It was also found that the active analogues exhibited their antiproliferative activity through a cytostatic non-apoptotic mechanism of action and maintained their potency against multi-drug resistant cells, which are poorly responsive to important clinical cancer drugs taxol and vinblastine. Although the detailed mechanistic studies aimed at the elucidation of mode(s) of action of the 2-aryl-2-(3-indolyl)acetohydroxamates are currently pursued in our labs, the compelling evidence for the effectiveness of these compounds against the apoptosis- and multidrug resistant cancer cells prompts us to disclose our findings in the present paper.</p><!><p>2-Aryl-2-(3-indolyl)acetohydroxamates (3, Figure 1) were identified to be intermediates in our recently discovered transannulation of indoles to 2-quinolones carried out by reacting 2-substituted indoles with β-nitrostyrenes in PPA at 100 °C.20 It was found that if the reaction temperature kept at 70 °C, compounds 3 could be isolated as the main reaction products (Figure 1A, Tables 1 and 2). The reaction scope was found to allow for the introduction of a variety of substituents R1, R2, R3 and R4 into the 2-aryl-2-(3-indolyl)acetohydroxamate scaffold 3. In addition, the recognition of limited access to a number of specific substituted indoles that would be required for systematic structure-activity relationship (SAR) analyses prompted the development of an alternative route based on an in situ Fisher indole synthesis utilizing arylhydrazines 4 and ketones 5 (Figure 1B). In this multicomponent variation, compounds 4 and 5 are reacted at 100 °C to allow for the indole formation and then the reaction temperature is lowered to 70 °C prior to the introduction of β-nitrostyrenes 2. Thus, the availability of two complementary approaches to compounds 3 permits the synthesis of analogues with the desired identity and positioning of substituents R1, R2, R3 and R4 on the 2-aryl-2-(3-indolyl)acetohydroxamate scaffold facilitating the development of these compounds as medicinal agents. Since the synthesized compounds have four diversification points, a four-dimensional tagging system is employed for labeling the products. Thus, the reaction of hydrazine 4aa with ketone 5f produces indole 1aaf, which in the subsequent reaction with nitrostyrene 2n affords hydroxamic acid 3aafn.</p><!><p>The evaluation of an initially synthesized series of compounds 3 for a variety of activities led to the identification of double-digit micromolar antiproliferative potencies associated with the parent acetohydroxamate 3aaaa (Table 1). This finding led to an exploration of the SAR analyses by synthesizing the first generation compounds 3 containing diverse substituents at different positions in the 2-aryl-2-(3-indolyl)acetohydroxamate skeleton and testing this series for in vitro growth inhibition using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay23 against two cell lines, human HeLa cervical and MCF-7 breast adenocarcinomas (Table 1). It emerged from these experiments that the substitution on the benzene ring of the indole moiety (R2 ≠ H) was not tolerated (e.g., 3abfa and 3acfa), whereas the nitrogen could be derivatized (R1 ≠ H) with only a small activity drop (e.g., 3bafa vs 3aafa). The key SAR finding resulted from the variations of the C2-position of the indole moiety (R3 ≠ Ph as in 3aaba, 3aaca, 3aada, 3aaea and 3aafa) and identification of single-digit micromolar potencies associated with compounds containing the β-naphthyl substituent at this position (as in 3aafa).</p><p>Based on the initial SAR in Table 1, the second generation compounds 3 were synthesized and they all contained an R2 = β-naphthyl, while R1 and R4 remained variable. These experiments led to the identification of a number of compounds possessing single-digit micromolar (e.g., 3aafe, 3aafk, 3aafm, 3aafn, 3aafo and 3aafp) or even submicromolar (e.g., 3aafe and 3aafp) activites, all containing meta and/or para-positioned R4. The addition of an R1 = alkyl (e.g., 3cafa, 3dafa, 3cafe and 3eafa) did not appear to be detrimental with GI50 values still in the single-digit micromolar region. Because of the significant lipophilicities associated with our acetohydroxamates and thus the possibility that the activities were a function of their lipophilic character, logP values were calculated for each analogue using three different methods, all giving similar results (Tables 1 and 2). The significant activity was indeed present among both less lipophilic analogues (e.g., 3aafc with logP = 4.1) and those with higher lipophilicity (e.g., 3cafe with logP = 8.4), thus ruling out such a possibility.</p><p>Finally, to assess the importance of the hydroxamic acid moiety, 3aafa was converted to nitrile 6 by treating the former with PCl3 and further to amide 7 by partial hydration of 6 in 80% PPA (Figure 2). The evaluation of nitrile 6 and amide 7 for antiproliferative activity revealed a 6- and 3-fold lower potencies associated with these compounds as compared with hydroxamate 3aafa, thus underscoring the importance of the hydroxamic acid moiety but not its criticality.</p><!><p>As part of the ongoing efforts in our lab aimed at identification of compounds active against cancer cell displaying resistance to proapoptotic agents,24–27 the selected 2-aryl-2-(3-indolyl)-acetohydroxamates were evaluated for in vitro growth inhibition against a panel of additional cancer cell lines including those resistant to various proapoptotic stimuli, such as human T98G and U87 glioblastoma28,29 and human A549 non-small-cell lung cancer (NSCLC),30 as well as an apoptosis-sensitive tumor model, such as human Hs683 anaplastic oligodendroglioma,28 used as reference. The obtained GI50 values associated with potent hydroxamates are shown in Table 3. The data reveal that for the most part these compounds retain the single-digit antiproliferatve GI50 values in this challenging cancer cell panel. Further analysis of the results from Tables 2 and 3 combined shows that the hydroxamates do not discriminate between the cancer cell lines based on the apoptosis sensitivity criterion and display comparable potencies in both cell types, indicating that apoptosis induction is not the primary mechanism responsible for antiproliferative activity in this series of compounds.</p><p>Our previous experience of working with cells resistant to various proapoptotic stimuli shows that generally a certain population of cells becomes rapidly eliminated with proapoptotic agents used at low concentrations leading to low GI50 values. However, these high potencies can be somewhat misleading as there often remains a significant portion of cells that resists the effects of the proapoptotic agents even at concentrations 100- or 1000-fold of their GI50s.31 It was thus instructive to compare the hydroxamates with common proapoptotic agents for their ability to affect such resistant populations. Indeed, as can be seen in Figure 3, hydroxamates 3aafa and 3aafp have potent growth inhibitory properties against most of the cells in U87 and A549 cultures and, with increasing concentration, rapidly reach antiproliferative levels of a non-discriminate cytotoxic agent phenyl arsine oxide (PAO). In contrast, common proapoptotic agents taxol and podophyllotoxin have no effect on proliferation of ca. 50% of cells in these cultures at concentrations up to 100 μM.</p><!><p>To obtain insight into the effectiveness of 2-aryl-2-(3-indolyl)acetohydroxamates against apoptosis-resistant cancers, computer-assisted phase-contrast microscopy12,13,15 (quantitative videomicroscopy) was employed to observe the phenotypic morphological changes in cancer cells as they are treated with these compounds. Figure 4 shows that acetohydroxamate 3aafa inhibits cancer cell proliferation without inducing cell death when assayed at concentrations slightly exceeding the GI50 values (25 μM) in SKMEL-28 melanoma and U373 glioblastoma cells, both exhibiting resistance to various proapoptotic stimuli.28,32 Based on the phase contrast pictures obtained by means of quantitative videomicroscopy, a global growth ratio (GGR) was calculated, which corresponds to the ratio of the mean number of cells present in a given image captured in the experiment (in this case after 24, 48 and 72 h) to the number of cells present in the first image (at 0 h). The ratio obtained in the 3aafa-treated experiment was then divided by the ratio obtained in the control. The GGR value of ca. 0.3 in both of these two cell lines indicates that 30% of cells grew in the 3aafa-treated experiment as compared to the control over a 72 h observation period. Thus, the GGR calculations are consistent with the MTT colorimetric data and indicate that it is the cytostatic properties associated with the hydroxamates that are responsible for their antiproliferative effects against apoptosis-resistant cancer cells at least at relevant concentrations (slightly above the GI50 values).</p><!><p>To elucidate the fate of the cells whose growth has been arrested with the hydroxamates, the phenotypic morphological changes of U87 glioma cells were observed for a period of several weeks after the treatment with hydroxamate 3aafa at the GI50 concentration. Interestingly, while untreated cells proliferated rapidly and quickly formed spheroids (Figure 5B), the treated cells ceased to replicate and appeared to undergo redifferentiation to a non-malignant state resembling a reactive astrocyte (data not shown) phenotype (Figure 5C). Although such redifferentiation processes are known, there are only a few small molecule agents reported to induce these epigenetic transformations.33,34 The literature reports indicate that these redifferentiated cells possess significantly reduced tumorigenicity in vivo33 and, thus, new chemical entities capable of triggering such phenotypic changes hold a promising but completely unexplored potential as anticancer agents.</p><!><p>Compared with the intrinsic drug resistance, as described above for such as cancers as glioblastoma and melanoma, a large variety of tumors can also develop resistance to anticancer drugs resulting in MDR as explained in the introduction. To assess whether the hydroxamates can overcome this resistance mechanism, selected hydroxamates were tested against MDR cells (Table 4). The MDR uterine sarcoma cell line MES-SA/Dx5 was utilized for this experiment. This cell line was established from the parent uterine sarcoma MES-SA, grown in the presence of increasing concentrations of doxorubicin and is known to be resistant to a number of P-gp substrates.35 Both taxol and vinblastine displayed more than a thousand fold drop in potency when tested for antiproliferative activity against the MDR cell line as compared with the parent line (Table 4). In contrast, there was only a small variation in the sensitivities of the two cell lines towards the hydroxamates indicating their potential to overcome clinical multi-drug resistance.</p><p>Given the ability of the hydroxamates to overcome drug resistance a few select compounds were further evaluated against glioma cells grown in neurosphere conditions, which are known to promote the growth of stem-like cells from human glioma tissue. Indeed, the neurospheres show the ability of self-renewal by regrowing in culture from individual cells, can differentiate into multiple neural lineages and recapitulate human gliomas on both histological and genetic levels more faithfully than serum cultured glioma cell lines when injected into the brains of mice.36–39 Because, neurosphere cells are generally resistant to radiation and chemotherapy,40–43 the micromolar to submicromolar activity of of the hydroxamates against the glioma neurosphere cell cultures is noteworthy (Table 4). The glioma culture 031810 used is derived from a patient with glioblastoma who progressed on temozolomide due to high O6-methylguanine-DNA-methyltransferase (MGMT) expression and thus shows high resistance to this agent (Table 4). It is worthy of note, that the unmethylated MGMT promoter leading to such temozolomide resistance is found in about half of all GBM patients, who respond poorly to temozolomide chemotherapy.44 To date, no alternative treatment exists for this group of patients.44</p><p>Finally, selected hydroxamates were tested against the normal human dermal (NHDF) and lung (NHLF) fibroblast cell lines in comparison with the cancerous glioma and NSCLC cells (Figure 6). The compounds displayed a modest but noteworthy selectivity in inhibiting the growth of cancer cells with 3aafa and 3aafp being particularly ineffective at inhibiting the proliferation of the normal NHDF cell line (Figure 6). These results show that the selectivity of the hydroxamates toward cancer cells is structure-dependent and can be optimized to select the best candidates for the forthcoming in vivo tests in animal models.</p><!><p>Drug resistance is one of the main causes for the failure of cancer chemotherapy, affecting patients with a broad variety of tumors. Resistance to chemotherapy can be intrinsic, in which cancers such as glioma, melanoma or NSCLC, among others, fail to respond to the first chemotherapy given. Resistance can also be acquired, in which tumors innately respond to chemotherapy but eventually become refractory to a broad spectrum of structurally and mechanistically diverse antitumor agents. The results presented herein demonstrate the potential 2-aryl-2-(3-indolyl)acetohydroxamates for the treatment drug-resistant cancer, regardless of whether the latter harbors intrinsic and acquired resistance mechanisms. The structural scaffold associated with these compounds represents a new chemotype, whose further investigation is warranted by the described findings and should be facilitated by the straightforward synthetic methodologies developed to accommodate systematic SAR studies as well as preparation of specific designed analogues. The ongoing work includes further optimization of compound potency, elucidation of mechanisms responsible for cytostatic and redifferentiation effects as well as experiments involving animal models of drug-resistant human cancer.</p><!><p>Reagents, solvents and catalysts were purchased from commercial sources (Acros Organics and Sigma-Aldrich) and used without purification. All reactions were performed in oven-dried flasks open to the atmosphere and monitored by thin layer chromatography on TLC precoated (250 μm) silica gel 60 F254 glass-backed plates (EMD Chemicals Inc.). Visualization was accomplished with UV light. Filtration was performed using silica gel (32–63 μm, 60 Å pore size). 1H and 13C NMR spectra were recorded on Bruker DRX-400 and Bruker DRX-500 spectrometers. Chemical shifts (δ) are reported in ppm relative to the TMS internal standard. Abbreviations are as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet). Indoles: 2-phenyl-1H-indole (1aaa), 2-(2-nitrophenyl)-1H-indole (3aab), 2-(4-methoxyphenyl)-1H-indole (3aac), 2-methyl-1H-indole (3aad), 2-(naphthalen-1-yl)-1H-indole (1aae), 2-(naphthalen-2-yl)-1H-indole (1aaf), 1-methyl-2-(naphthalen-2-yl)-1H-indole (1baf), and 5-methoxy-2-(naphthalen-2-yl)-1H-indole (1acf) were purchased from commercial sources and used as received. Procedures for preparation of 5-methyl-2-(naphthalen-2-yl)-1H-indole (1abf), 1-butyl-2-(naphthalen-2-yl)-1H-indole (1caf), 1-(sec-butyl)-2-(naphthalen-2-yl)-1H-indole (1daf), 1-benzyl-2-(naphthalen-2-yl)-1H-indole (1eaf) are provided below. Ketones: acetophenone (5a), o-nitroacetophenone (5b), p-methoxyacetophenone (5c), acetone (5d), 1-acetylnaphalene (5e), and 2-acetylnaphalene (5f) were obtained from commercial sources and used as received. Arylhydrazines: pehylhydrazine (4aa), p-tolylhydrazine (4ab), and p-anisylhydrazine (4ac) were obtained from commercial sources and used as received. Nitroalkenes: (2-nitrovinyl)benzene (2a), 1-nitro-4-(2-nitrovinyl)benzene (2b), 1-fluoro-3-(2-nitrovinyl)benzene (2c), 1-bromo-2-(2-nitrovinyl)benzene (2d), 1,2-dimethoxy-4-(2-nitrovinyl)benzene (2f), 1-chloro-2-(2-nitrovinyl)benzene (2h), 1,2-dichloro-4-(2-nitrovinyl)benzene (2i), 1-(2-nitrovinyl)-4-(trifluoromethoxy)benzene (2j), 1-methyl-4-(2-nitrovinyl)benzene (2m), N,N-dimethyl-4-(2-nitrovinyl)aniline (2p) were acquired from commercial sources and used as received. 1-Isopropyl-4-(2-nitrovinyl)benzene (2e), 1-fluoro-4-(2-nitrovinyl)benzene (2g), 1,2-dimethyl-4-(2-nitrovinyl)benzene (2k), 1-ethoxy-4-(2-nitrovinyl)benzene (2l), 1-methyl-3-(2-nitrovinyl)benzene (2n) were synthesized using a reported procedure,45 as well as N,N-diethyl-4-(2-nitrovinyl)aniline (2o).46 Elemental analyses were performed using a CHN-1 analyzer. HRMS analyses were performed on ESI Bruker Maxis. The synthesized compounds were at least 95% pure according to elemental analyses and/or HPLC chromatograms.</p><!><p>A mixture of 4-methylphenylhydrazine (4ab) (1.22 g, 10 mmol) and 2-acetylnaphthalene (5f) (1.70 g, 10 mmol) was vigorously stirred at 100–110 °C in 80% PPA (3–5 g) for 40 min. When the reaction was complete based on TLC analysis the mixture was cooled down to rt, poured into water (50 mL), and neutralized with aqueous ammonia. The formed precipitate was filtered, dried in vacuum, and used without additional purification. Yield 2.44 g (9.5 mmol, 95%); m.p. = 212–213 °C (toluene); 1H NMR (400 MHz, CDCl3) δ, ppm: 8.43 (br. s, 1H), 8.08 (s, 1H), 7.93-7.86 (m, 4H), 7.56-7.48 (m, 2H), 7.46 (s, 1H), 7.30-7.34 (m, 1H), 7.07 (d, J = 8.2 Hz, 1H), 6.9 (s. 1H), 2.49 (s. 3H); 13C NMR (100 MHz, CDCl3) δ: 133.7, 129.8, 128.9, 128.7, 128.4, 128.1, 127.9, 126.8, 126.7, 126.4, 126.3, 125.4, 124.9, 124.4, 123.9, 120.6, 118.2, 111.0, 21.6; HRMS calc'd for C19H16N (M+H)+: 258.1277, found 258.1276.</p><!><p>To a stirred solution of KOH (2.24 g, 40 mmol) in DMSO (20 mL was added 2-(2-naphthyl)indole (1aaf) (2.43 g, 10 mmol), and the mixture was stirred for 45 min. Then, n-butyl bromide (2.7 g, 20 mmol) was added and the stirring was continued for additional 45 min. The mixture was diluted with water (20 mL) and extracted with benzene (3 × 50 mL). Combined organic layers were washed with water (3 × 100 mL), dried with CaCl2 and concentrated in vacuum to obtain the titled compound as yellowish oil. Yield 2.60 g (8.7 mmol, 87%); 1H NMR (400 MHz, CDCl3) δ, ppm: 7.99-7.92 (m, 4H), 7.77 (d, J = 7.8 Hz, 1H), 7.65 (dd, J = 8.4, 1.7 Hz, 1H), 7.58-7.55 (m, 2H), 7.45 (d, J = 8.2 Hz, 1H), 7. 28 (ddd, J = 7.4, 7.6, 1.1 Hz, 1H), 7.19 (ddd, J = 7.4, 7.4, 0.9 Hz, 1H), 6.65 (s, 1H), 4.25 (t, J = 7.5 Hz, 2H), 1.74 (m, 2H), 1.21 (m, 2H), 0.82 (t, J = 7.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ: 141.5, 137.7, 133.4, 132.9, 130.9, 128.5, 128.4, 128.3, 128.2, 127.9, 127.4, 126.6, 126.5, 121.7, 120.7, 119.9, 110.2, 102.7, 44.1, 32.3, 20.1, 13.8; HRMS calc'd for C22H22N (M+H)+: 300.1747, found 300.1749.</p><!><p>To a stirred solution of KOH (2.24 g, 40 mmol) in DMSO (20 mL was added 2-(2-naphthyl)indole (1aaf) (2.43 g, 10 mmol), and the mixture was stirred for 45 min. Then, sec-butyl bromide (2.7 g, 20 mmol) was added and the stirring was continued for additional 60 min. The mixture was idluted with water (20 mL) and extracted with benzene (3 × 50 mL). Combined organic layers were washed with water (3 × 100 mL), dried with CaCl2 and concentrated in vacuum to obtain the titled compound as colorless solid. Yield 2.52 g (8.4 mmol, 84%); m.p. = 103–104 °C (petroleum ether); 1H NMR (400 MHz, CDCl3) δ, ppm: 7.99-7.91 (m, 4H), 7.69, (d, J = 7.9 Hz, 1H), 7.63 (dd, J = 8.4, 1.5 Hz, 1H), 7.59-7.55 (m, 3H), 7.44 (d, J = 8.2 Hz, 1H), 7.27 (ddd, J = 7.6, 7.5, 0.7 Hz, 1H) 7.18 (t, J = 7.3 Hz, 1H), 6.66 (s, 1H), 4.15-4.13 (m, 2H), 2.15-2.04 (m, 1H), 0.69-067 (m, 6H); 13C NMR (100 MHz, CDCl3) δ: 141.8, 138.0, 133.4, 132.9, 131.22, 128.7, 128.4, 128.3, 128.2, 127.9, 127.6, 126.6, 126.5, 121.6, 120.7, 119.9, 110.7, 103.0, 51.5, 29.1, 22.9, 20.2; HRMS calc'd for C22H22N (M+H)+: 300.1747, found 300.1750.</p><!><p>To a stirred solution of KOH (2.24 g, 40 mmol) in DMSO (20 mL was added 2-(2-naphthyl)indole (1aaf) (2.43 g, 10 mmol), and the mixture was stirred for 45 min. Then, benzyl bromide (3.4 g, 20 mmol) was added and the stirring was continued for additional 45 min. The mixture was diluted with water (20 mL) and extracted with benzene (3 × 50 mL). Combined organic layers were washed with water (3 × 100 mL), dried with CaCl2 and concentrated in vacuum to obtain the titled compound as colorless solid. Yield 3.07 g (9.2 mmol, 92%); m.p. = 144–146 °C (toluene); 1H NMR (400 MHz, CDCl3) δ, ppm: 7.89-7.84 (m, 3H), 7.76-7.70 (m, 2H), 7.57 (dd, J = 8.5, 1.7 Hz, 1H), 7.51-7.49 (m, 2H), 7.32-7.24 (m, 4H), 7.20-7.17 (m, 2H), 7.08 (d, J = 6.8 Hz, 2H), 6.77 (s, 1H), 5.43 (s, 2H); 13C NMR (100 MHz, CDCl3) δ: 142.0, 138.4 (2C), 133.3, 133.0, 130.2, 128.9 (2C), 128.5, 128.4, 128.3 (2C), 127.8, 127.4, 127.2, 126.6, 126.5, 126.2 (2C), 122.2, 120.7, 120.4, 110.7, 102.9, 48.1; HRMS calc'd for C25H20N (M+H)+: 334.1590, found 334.1595.</p><!><p>A mixture of a selected indole 1 (1 mmol) and a selected nitrostyrene 2 (1.2 mmol) in 80% PPA (3–4 g) was stirred at 65–70 °C for 1 h. The disappearance of the starting indole was monitored by TLC. After the indole has reacted completely, the mixture was cooled to rt, poured in water (50 mL) and treated with saturated NH4OH to pH 8. The formed precipitate was filtered and recrystallized from the indicated solvent.</p><!><p>A mixture of a selected arylhydrazine 4 (1 mmol) and a selected methylaryl ketone 5 (1 mmol) in 80% PPA (2–3 g) was stirred at 100–110 °C for 40 min. The disappearance of the starting arylhydrazine was monitored by TLC. After the arylhydrazine has reacted completely, the temperature was decreased to 65–70 °C and a selected nitrostyrene 2 (1.2 mmol) was added. The mixture was stirred at this temperature for 1 h and the disappearance of the intermediate indole 1 was monitored by TLC. After the indole has reacted completely, the mixture was cooled to room temperature, poured in water (50 mL) and treated with saturated NH4OH to pH 8. The formed precipitate was filtered and recrystallized from the indicated solvent.</p><!><p>Synthesized according to the general method A from 2-phenylindole (3aaa) and (2-nitrovinyl)benzene (2a) in 82% yield; Alternatively prepared according to the general method B starting from phenylhydrazine (4aa), acetophenone (5a) and (2-nitrovinyl)benzene (2a): 76%; m.p. = 220–221°C (toluene/petroleum ether); 1H NMR (500 MHz, CDCl3) δ, ppm: 11.30 (br. s, 1H), 10.75 (br. s, 1H), 8.81 (br. s, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7.54-7.48 (m, 4H), 7.41 (dd, J = 7.2, 7.1 Hz, 1H), 7.35 (d, J = 8.1 Hz, 1H), 7.27-7.16 (m, 5H), 7.06 (dd, J = 7.6, 7.4 Hz, 1H), 6.88 (t, J = 7.4 Hz, 1H), 5.10 (s, 1H); 13C NMR (125 MHz, CDCl3) δ, ppm: 168.6, 140.7, 136.2, 132.5, 128.6 (23), 128.5 (23), 128.0 (23), 127.9 (23), 127.7, 127.6, 126.1, 122.3, 121.1, 118.5, 110.9, 109.2, 46.0; EA: Calcd for C22H18N2O2: C 77.17, H 5.30, N 8.18. Found: C 77.33, H 5.22, N 8.11; HRMS calc'd for C22H18N2O2Na (M+Na)+: 365.1260, found 365.1272.</p><!><p>According to the method A, starting from 2-phenyl-1H-indole (3aaa) and 1-nitro-4-(2-nitrovinyl)benzene (2b): 73%; According to the method B, starting from phenylhydrazine (4aa), acetophenone (5a) and 1-nitro-4-(2-nitrovinyl)benzene (2b): 68%; m.p. = 156–157 °C (toluene); 1H NMR (400 MHz, DMSO) δ, ppm: 11.44 (br. s, 1H), 10.89 (br. s, 1H), 8.96 (br. s, 1H), 8.14 (d, J = 8.8 Hz, 2H), 7.65 (d, J = 8.0 Hz, 1H), 7.49-7.46 (m, 4H), 7.42-7.36 (m, 5H), 7.09 (t, J = 7.2 Hz, 1H), 6.92 (t, J = 7.5 Hz,1H), 5.20 (s, 1H); 13C NMR (100 MHz, DMSO) δ: 167.8, 148.6, 146.0, 136.7, 136.2, 132.2, 129.3 (2C), 128.7 (4C), 127.9, 127.4, 123.3 (2C), 121.6, 121.4, 118.9, 111.2, 108.0, 46.1; HRMS calc'd for C22H17N3O4Na (M+Na)+: 410.1111, found 410.1111.</p><!><p>According to the method A, starting from 2-(2-nitrophenyl)-1H-indole (3aab) and (2-nitrovinyl)benzene (2a): 68%; According to the method B, starting from phenylhydrazine (4aa), 2-nitroacetophenone (5b) and (2-nitrovinyl)benzene (2a): 61%; m.p. = 118–119 °C (toluene); 1H NMR (400 MHz, DMSO) δ, ppm: 11.27 (br. s, 1H), 10.71 (br. s, 1H), 8.87 (br. s, 1H), 8.12 (dd, J = 8.1, 0.9 Hz, 1H), 7.80-7.61 (m, 4H), 7.54 (d, J = 7.4 Hz, 2H), 7.29 (d, J = 8.0 Hz, 1H), 7.18-7.06 (m, 5H), 6.91 (t, J = 7.4 Hz, 1H), 4.77 (s, 1H); 13C NMR (100 MHz, DMSO) δ: 166.4, 147.6, 139.9, 136.2, 134.2, 133.7, 133.1, 129.8, 127.8 (2C), 127.7 (3C), 127.0 (2C), 126.1, 124.5, 121.4, 118.5, 111.2, 110.9, 45.9; HRMS calc'd for C22H17N3O4Na (M+Na)+: 410.1111, found 410.1109.</p><!><p>According to the method A, starting from 2-(4-methoxyphenyl)-1H-indole (3aac) and (2-nitrovinyl)benzene (2a): 43%; According to the method B, starting from phenylhydrazine (4aa), 4-methoxyacetophenone (5c) and (2-nitrovinyl)benzene (2a): 35%; m.p. = 133–134 °C (toluene); 1H NMR (400 MHz, DMSO) δ, ppm: 11.22 (br. s, 1H), 10.73 (br. s, 1H), 8.81 (br. s, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.43 (d, J = 8.5 Hz, 2H), 7.32 (d, J = 8.0 Hz, 1H), 7.27-7.17 (m, 5H), 7.06-7.01 (m, 3H), 7.86 (t, J = 7.5 Hz, 1H), 5.04 (s, 1H), 3.81 (s, 3H); 13C NMR (100 MHz, DMSO) δ: 169.1, 159.4, 141.3, 136.7, 136.5, 130.4 (2C), 128.5 (2C), 128.4 (2C), 128.3, 126.6, 125.4, 122.6, 121.3, 118.9, 114.6 (2C), 111.2, 109.0, 55.7, 46.6; HRMS calc'd for C23H20N2O3Na (M+Na)+: 395.1373, found 395.1366.</p><!><p>According to the method A, starting from 2-methyl-1H-indole (3aad) and (2-nitrovinyl)benzene (2a): 46%; According to the method B, starting from phenylhydrazine (4aa), acetone (5d) and (2-nitrovinyl)benzene (2a): 27%; m.p. = 110–112 °C (toluene); 1H NMR (400 MHz, DMSO) δ, ppm: 10.86 (br. s, 1H), 10.79 (br. s, 1H), 8.86 (br. s, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.37 (s, 1H), 7.26-7.20 (m, 5H), 6.94 (ddd, J = 7.4, 7.4, 0.6 Hz, 1H), 6.83 (t, J = 7.2 Hz, 1H), 4.93 (s, 1H), 2.30 (s, 3H); 13C NMR (100 MHz, DMSO) δ: 168.7, 140.5, 135.1, 133.2, 128.1 (2C), 127.9 (2C), 127.7, 126.1, 119.9, 119.8, 118.0, 110.2, 108.5, 45.3, 11.9; HRMS calc'd for C22H17N3O4Na (M+Na)+: 303.1104, found 303.1103.</p><!><p>According to the method A, starting from 2-(1-naphthyl)-1H-indole (3aae) and (2-nitrovinyl)benzene (2a): 76%; According to the method B, starting from phenylhydrazine (4aa), 1-acetylnaphthalene (5e) and (2-nitrovinyl)benzene (2a): 70%; m.p. = 110–112 °C (toluene); 1H NMR (400 MHz, DMSO, 338K) δ, ppm: 11.28 (br. s, 1H), 10.41 (br. s, 1H), 8.63 (br. s, 1H), 8.03-7.99 (m, 2H), 7.79-7.50 (m, 5H), 7.40-7.33 (m, 2H), 7.26-7.07 (m, 6H), 6.93 (t, J = 7.4 Hz, 1H), 4.73 (s, 1H); 13C NMR (100 MHz, DMSO) δ: 168.8, 140.3, 136.3, 134.9, 133.2, 132.5, 130.0, 129.2, 128.6, 128.5, 128.1, 127.9 (2C), 127.2, 126.4, 126.0 (2C), 125.7, 125.5, 125.2, 122.4, 121.1, 118.4, 111.4, 110.8, 46.2; HRMS calc'd for C26H20N2O2Na (M+Na)+: 415.1417, found 415.1417.</p><!><p>According to the method A, starting from 2-(2-naphthyl)-1H-indole (3aaf) and (2-nitrovinyl)benzene (2a): 85%; According to the method B, starting from phenylhydrazine (4aa), 2-acetylnaphthalene (5f) and (2-nitrovinyl)benzene (2a): 73%; m.p. = 152–154 °C (toluene). 1H NMR (500 MHz, DMSO) δ, ppm: 11.31 (br. s, 1H), 10.76 (br. s, 1H), 8.82 (br. s, 1H), 8.03-7.97 (m, 3H), 7.91 (dd, J = 8.8, 2.1 Hz, 1H), 7.77 (d, J = 8.1 Hz, 1H), 7.68 (dd, J = 8.5, J = 1.3 Hz, 1H), 7.58-7.56 (m, 2H), 7.38 (d, J = 8.1 Hz, 1H), 7.29-7.17 (m, 5H), 7.09 (dd, J = 7.8, 7.4 Hz, 1H), 6.91 (dd, J = 7.8, 7.5 Hz, 1H), 5.19 (s, 1H); 13C NMR (125 MHz, DMSO) δ: 168.5, 140.8, 136.4, 135.9, 132.8, 132.2, 130.0, 128.1, 128.0 (23), 127.9, 127.8, 127.6, 127.5, 127.4 126.6, 126.4, 126.3, 126.2, 122.3, 121.3, 118.6, 110.9, 109.9, 99.9, 45.8; EA: Calcd for C26H20N2O2: C 79.57, H 5.14, N 7.14. Found: C 79.68, H 5.09, N 7.16; HRMS calc'd for C26H20N2O2Na (M+Na)+: 415.1417, found 415.1419.</p><!><p>According to the method A, starting from 5-methyl-2-(2-naphthyl)-1H-indole (3abf) and (2-nitrovinyl)benzene (2a): 79%; According to the method B, starting from 4-tolyl-hydrazine (4ab), 2-acetylnaphthalene (5f) and (2-nitrovinyl)benzene (2a): 73%; m.p. = 133–135 °C (toluene); 1H NMR (400 MHz, DMSO) δ, ppm: 11.34 (br. s, 1H), 10.75 (br. s, 1H), 8.82 (br. s, 1H), 8.00-7.87 (m, 5H), 7.65 (dd, J = 8.65, 1.08 Hz, 1H), 7.60 (s, 1H), 7.57-7.54 (m, 2H), 7.29-7.17 (m, 6H), 7.92 (dd, J = 8.2, 0.9 Hz, 1H), 5.17 (s, 1H), 2.31 (s, 3H); 13C NMR (100 MHz, DMSO) δ: 169.1, 141.4, 136.7, 135.3 (2C), 133.3, 132.7, 130.6, 128.6 (4C), 128.5, 128.4, 128.1, 127.9, 127.3, 127.1, 127.0, 126.8, 126.7, 123.5, 122.2, 111.2, 109.8, 46.7, 22.0; HRMS calc'd for C27H22N2O2Na (M+Na)+: 429.1573, found 439.1577.</p><!><p>According to the method B, starting from (4-methoxyphenyl)hydrazine (4ac), 2-acetylnaphthalene (5e) and (2-nitrovinyl)benzene (2a): 28%; m.p. = 128–130 °C (toluene); 1H NMR (400 MHz, DMSO) δ, ppm: 11.31 (br. s, 1H), 10.80 (br. s, 1H), 8.85 (br. s, 1H), 8.01-7.88 (m, 4H), 7.65 (d, J =8.59 Hz, 1H), 7.59-7.53 (m, 2H), 7.37 (s, 1H), 7.30-7.17 (m, 5H), 7.75 (dd, J = 8.7, 2.4 Hz, 1H), 5.16 (s, 1H), 3.64 (s, 3H); 13C NMR (100 MHz, DMSO) δ: 168.6, 152.8, 140.8, 136.8, 132.8, 132.2, 131.7, 130.1, 128.4, 128.3, 128.1 (4C), 128.0, 127.6, 127.3, 126.6, 126.5, 126.3, 126.2, 111.5, 111.2, 109.6, 104.5, 55.2, 46.3; HRMS calc'd for C27H22N2O3Na (M+Na)+: 445.1523, found 445.1523</p><!><p>According to the method A, starting from N-methyl-2-(2-naphthyl)-1H-indole (3baf) and 3-fluoro(2-nitrovinyl)benzene (2c): 54%; m.p. = 133–134 °C (toluene/petroleum ether); 1H NMR (400 MHz, DMSO) δ, ppm: 10.69 (br. s, 1H), 8.89 (br. s, 1H), 8.07-7.92 (m, 4H), 7.73 (d, J = 8.0 Hz, 1H), 7.61 (m, 2H), 7.50 (d, J = 8.2 Hz, 2H), 7.26-7.17 (m, 4H), 7.08 (d, J = 7.3 Hz, 1H), 7.0 (t, J = 7.3 Hz, 1H), 4.84 (s, 1H), 3.59 (s. 3H); 13C NMR (100 MHz, DMSO) δ: 167.7, 159.8 (d, 1JCF = 247.2 Hz), 138.8, 136.9, 132.6, 132.5, 130.2, 129.9, 128.4 (d, 3JCF = 6.9 Hz), 128.2, 128.1, 127.9, 127.8, 127.6, 127.5, 126.7, 126.6, 126.5, 123.8, 121.4, 120.9, 119.2, 114.7 (d, 2JCF = 22.3 Hz), 109.8, 108.9, 40.4, 30.9; HRMS calc'd for C27H21FN2O2Na (M+Na)+: 447.1479, found 447.1493.</p><!><p>According to the method A, starting from N-methyl-2-(2-naphthyl)-1H-indole (3baf) and (2-nitrovinyl)benzene (2a): 75%; m.p. = 114–115 °C (toluene/petroleum ether); 1H NMR (400 MHz, DMSO) δ, ppm: 10.66 (br. s, 1H), 8.84 (br. s, 1H), 8.03-7.91 (m, 4H), 7.77 (d, J = 8.1 Hz, 1H), 7.62-7.60 (m, 2H), 7.52 (d, J = 8.8 Hz, 1H), 7.48 (d, J = 8.1 Hz, 1H), 7.26-7.14 (m, 7H), 6.98 (dd, J = 7.8, 7.5 Hz, 1H), 4.85 (s, 1H), 3.60 (s, 3H); 13C NMR (100 MHz, DMSO) δ: 168.5, 140.7, 138.8, 137.1, 132.6, 132.5, 130.0, 128.4, 128.2, 128.1, 127.9 (4C), 127.6, 126.7, 126.5 (2C), 126.1, 122.3, 121.3, 118.8, 110.8, 109.5, 99.5, 46.4, 30.8; EA: Calcd for C27H22N2O2: C 79.78, H 5.46, N 6.89. Found: C 80.03, H 5.39, N 6.81; HRMS calc'd for C27H22N2O2Na (M+Na)+: 429.2416, found 429.2418.</p><!><p>According to the method A, starting from N-methyl-2-(2-naphthyl)-1H-indole (3baf) and 2-bromo(2-nitrovinyl)benzene (2d): 36%; m.p. = 109–113 °C (toluene/petroleum ether); 1H NMR (400 MHz, CDCl3) δ, ppm: 7.91 (d, J = 8.2 Hz, 2H), 7.80 (d, J = 7.00 Hz, 1H), 7.69-7.64 (m, 1H), 7.59-7.49 (m, 5H), 7.42 (d, J = 8.2 Hz, 1H), 7.30 (d, J = 8.2 Hz, 1H), 7.30 (d, J = 7.6 Hz, 1H), 7.17-7.13 (m, 2H), 7.09-7.06 (m, 1H), 5.43 (s, 1H), 3.68 (s, 3H); 13C NMR (100 MHz, DMSO) δ, ppm: 167.6, 139.8, 139.0, 137.0, 132.5, 132.4, 132.3, 130.9, 129.8, 128.4, 128.2, 128.1, 127.8, 127.6, 127.5, 127.2, 126.8, 126.6, 126.4, 123.9, 121.4, 120.2, 119.4, 110.0, 109.5, 47.1, 31.0; HRMS calc'd for C27H21BrN2O2Na (M+Na)+: 507.0679, found 507.0677.</p><!><p>According to the method A, starting from 2-(2-naphthyl)-1H-indole (3aaf) and 4-isopropyl(2-nitrovinyl)benzene (2a): 73%; According to the method B, starting from phenylhydrazine (4aa), 2-acetylnaphthalene (5f) and 4-isopropyl(2-nitrovinyl)benzene (2e): 61%; m.p. = 147–148 °C (toluene/petroleum ether). 1H NMR (400 MHz, DMSO) δ, ppm: 11.44 (br. s, 1H), 10.76 (br. s, 1H), 8.82 (br. s, 1H), 8.02-7.9 (m, 4H), 7.82 (d, J = 8.1 Hz, 1H), 7.66 (dd, J = 8.5, 1.59 Hz, 1H) 7.60-7.53 (m, 2H), 7.38 (d, J = 8.1 Hz, 1H), 7.17-7.06 (m, 5H), 6.92 (ddd, J = 15.0, 7.5, 0.5 Hz, 1H), 5.16 (s, 1H), 2.86-2.76 (m, 1H), 1.14 (d, J = 6.9 Hz, 6H); 13C NMR (100 MHz, DMSO) δ, ppm: 168.8, 146.2, 138.1, 136.4, 136.0, 132.8, 132.2, 130.1, 128.1, 128.0 (2C), 127.9, 127.6, 127.5, 126.7, 126.5, 126.3, 125.9 (2C), 122.4, 121.3, 118.6, 111.0, 110.0, 45.9, 39.9, 33.0, 23.9 (2C); Calc'd for C29H26N2O2: C 80.16, H 6.03, N 6.45. Found: C 80.31, H 5.95, N 6.36; HRMS calc'd for C29H26N2O2Na (M+Na)+: 457.1884, found 457.1887.</p><!><p>According to the method A, starting from 2-(2-naphth yl)-1H-indole (3aaf) and 3,4-dimethoxy(2-nitrovinyl)benzene (2f): 60%; According to the method B, starting from phenylhydrazine (4aa), 2-acetylnaphthalene (5f) and 3,4-dimethoxy(2-nitrovinyl)benzene (2f): 56%; m.p. = 143–144 °C (toluene); 1H NMR (400 MHz, DMSO) δ, ppm: 11.44 (br. s, 1H), 10.70 (br. s, 1H), 8.81 (br. s, 1H), 8.02-7.89 (m, 4H), 7.85 (d, J = 8.1 Hz, 1H), 7.67 (dd, J = 8.5, 1.4 Hz, 1H), 7.59-7.54 (m, 2H), 7.38 (d, J = 8.0 Hz, 1H), 7.09 (t, J = 7.2 Hz, 1H), 6.94 (t, J = 7.3 Hz, 1H), 6.85-6.83 (m, 2H), 7.76 (dd, J = 8.4, 1.5 Hz, 1H), 5.12 (s, 1H), 3.68 (s, 3H), 3.59 (s, 3H); 13C NMR (100 MHz, DMSO) δ: 168.8, 148.3, 147.4, 136.4, 136.0, 133.1, 132.8, 132.2, 130.1, 128.1, 127.9, 127.8, 127.6, 127.5, 126.7, 126.5, 126.3, 122.2, 121.3, 120.4, 118.6, 112.4, 111.6, 111.0, 110.2, 55.5, 55.4, 45.9; HRMS calc'd for C28H24N2O4Na (M+Na)+: 475.1628, found 475.1635</p><!><p>According to the method A, starting from 2-(2-naphthyl)-1H-indole (3aaf) and 4-fluoro(2-nitrovinyl)benzene (2g): 76%; According to the method B, starting from phenylhydrazine (4aa), 2-acetylnaphthalene (5f) and 4-fluoro(2-nitrovinyl)benzene (2g): 64%; m.p. = 138–139°C (toluene/petroleum ether); 1H NMR (400 MHz, DMSO) δ, ppm: 11.50 (br. s, 1H), 10.80 (br. s, 1H), 8.88 (br. s, 1H), 8.04-7.97 (m, 4H), 7.92 (dd, J = 8.8, 2.1 Hz, 1H), 7.76 (d, J = 8.1 Hz, 1H), 7.67 (dd, J = 8.5, J = 1.3 Hz, 1H), 7.59-7.55 (m, 2H), 7.39 (d, J = 8.1 Hz, 1H), 7.27-7.23 (m, 2H), 7.13-7.08 (m, 3H), 6.93 (dd, J = 7.8, 7.5 Hz, 1H), 5.18 (s, 1H); 13C NMR (100 MHz, DMSO) δ: 168.4, 160.7 (d, 1JCF = 242.5 Hz), 136.9 (d, 4JCF = 3.0 Hz), 136.4, 136.2, 132.8, 132.2, 130.0, 129.8 (d, 3JCF = 8.1 Hz, 2C), 128.1, 128.0, 127.7, 127.6, 127.5, 126.6, 126.5, 126.4, 122.0, 121.4, 118.8, 114.8 (d, 2JCF = 21.6 Hz, 2C), 111.0, 109.7, 45.5; EA: Calcd for C26H19FN2O2: C 76.08, H 4.67, N 6.83. Found: C 76.23, H 4.62, N 6.76; HRMS calc'd for C26H19FN2O2Na (M+Na)+: 432.1244, found 432.2432.</p><!><p>According to the method A, starting from 2-(2-naphthyl)-1H-indole (3aaf) and 2-chloro(2-nitrovinyl)benzene (2h): 84%; According to the method B, starting from phenylhydrazine (4aa), 2-acetylnaphthalene (5f) and 2-chloro(2-nitrovinyl)benzene (2h): 72%; m.p. = 164–166 °C (toluene/petroleum ether). 1H NMR (500 MHz, DMSO) δ, ppm: 11.59 (br. s, 1H), 10.67 (br. s, 1H), 8.80(br. s, 1H), 8.01-7.94 (m, 2H), 7.79 (d, J = 8.6 Hz, 2H), 7.60-7.54 (m, 4H), 7.45 (t, J = 8.2 Hz, 2H), 7.39(dd, J = 1.6, 5.5 Hz, 2H), 7.29-7.23 (m, 3H), 7.14 (t, J = 7.3 Hz, 1H), 6.85(t, J = 7.6 Hz, 1H), 5.46 (s, 1H); 13C NMR (125 MHz, DMSO) δ: 167.5, 138.4, 136.3, 136.1, 133.0, 132.8, 132.2, 131.0, 129.9, 129.1, 128.4, 128.1, 128.0, 127.9, 127.6, 127.0, 126.6, 126.4, 126.2, 121.5, 120.8, 119.2, 111.3, 108.8, 99.5, 44.6; EA: Calcd for C26H19ClN2O2: C 73.15, H 4.49, N 6.56. Found: C 73.26, H 4.42, N 6.61; HRMS calc'd for C26H19ClN2O2Na (M+Na)+: 449.1027, found 449.1012.</p><!><p>According to the method A, starting from 2-(2-naphthyl)-1H-indole (3aaf) and 3,4-dichloro(2-nitrovinyl)benzene (2i): 45%; According to the method B, starting from phenylhydrazine (4aa), 2-acetylnaphthalene (5f) and 3,4-dichloro(2-nitrovinyl)benzene (2i): 43%; m.p. = 144–150 °C (toluene/petroleum ether). 1H NMR (500MHz, DMSO) δ, ppm: 11.58 (br. s, 1H), 10.85 (br. s, 1H), 8.97 (br. s, 1H), 8.01 (s, 1H), 7.98-7.91 (m, 2H), 7.73 (d, J = 8.1 Hz,1H), 7.65 (d, J = 8.3 Hz, 2H), 7.58-7.52 (m, 3H), 7.43-7.36 (m, 2H), 7.18-7.11 (m, 2H), 6.97 (t, J = 7.4 Hz, 1H), 5.21 (s, 1H); 13C NMR (125 MHz, DMSO) δ: 167.8, 141.8, 136.6, 136.4, 132.8, 132.3, 130.7, 130.4, 129.9, 129.7, 129.0, 128.6, 128.3, 128.1, 127.7, 127.6, 127.5, 126.6 (2C), 126.5, 121.6, 121.6, 119.1, 111.3, 108.6, 45.5; EA: Calcd for C26H18Cl2N2O2: C 67.69, H 3.93, N 6.07. Found: C 67.83, H 3.87, N 6.15; HRMS calc'd for C26H18Cl2N2O2Na (M+Na)+: 483.0638, found 483.0643, 485.0662.</p><!><p>According to the method A, starting from 2-(2-naphthyl)-1H-indole (3aaf) and 3-fluoro(2-nitrovinyl)benzene (2c): 75%; According to the method B, starting from phenylhydrazine (4aa), 2-acetylnaphthalene (5f) and 3-fluoro(2-nitrovinyl)benzene (2c): 64%; m.p. = 126–127 °C (toluene/petroleum ether). 1H NMR (400 MHz, DMSO) δ, ppm: 11.54 (br. s, 1H), 10.86 (br. s., 1H), 8.92 (br. s., 1H), 8.03-7.90 (m, 4H), 7.74 (d, J= 8.1 Hz, 1H), 7.65 (dd, J= 8.4, 1.7 Hz, 1H), 7.60-7.54 (m, 2H), 7.41-7.28 (m, 2H), 7.25 (dd, J= 5.1, 1.4 Hz, 2H), 7.16 (d, J= 7.5 Hz, 1H), 7.11 (ddd, J= 7.5, 7.5, 0.8 Hz, 1H), 6.95 (ddd, J= 11.4, 7.6, 0.6 Hz, 1H), 5.19 (s., 1H); 13C NMR (100 MHz, DMSO) δ: 168.1, 162.0 (1JCF = 242.0 Hz) 143.7 (d, 3JCF = 6.0 Hz), 136.4, 132.8, 132.3, 130.0, 129.9, 129.8, 128.0 (2C), 127.7, 127.6 (2C), 126.6, 126.5, 126.4, 124.2, 121.9, 121.4, 118.8, 114.7 (d, 2JCF = 21.8 Hz), 113.1 (d, 2JCF = 20.7 Hz), 111.1, 109.2, 46.0; HRMS calc'd for C26H19FN2O2Na (M+Na)+: 433.1323, found 433.1337.</p><!><p>According to the method A, starting from 2-(2-naphthyl)-1H-indole (3aaf) and 4-(trifluoromethoxy)(2-nitrovinyl)benzene (2j): 56%; According to the method B, starting from phenyl-hydrazine (4aa), 2-acetylnaphthalene (5f) and 4-(trifluoromethoxy)(2-nitrovinyl)benzene (2j): 52%; m.p. = 136–137°C (toluene/petroleum ether).1H NMR (400 MHz, DMSO) δ, ppm: 11.52 (br. s., 1H), 10.83 (br. s., 1H), 8.9 (br. s., 1H), 8.02-7.90 (m, 4H), 7.75 (d, J = 8.08 Hz, 1H), 7.65 (dd, J = 9.2, 1.2 Hz, 1H), 7.59-7.54 (m, 2H), 7.40 (d, J = 8.1 Hz, 1H), 7.33 (d, J= 8.8 Hz, 2H), 7.26 (d, J = 8.3 Hz, 2H), 7.10 (ddd, J = 7.6, 7.5, 0.5 Hz, 1H), 6.94 (t, J = 7.4 Hz, 1H), 5.22 (s, 1H); 13C NMR (100 MHz, DMSO) δ, ppm: 168.2, 146.7, 140.1, 136.4 (2C),, 136.3, 132.8, 132.2, 129.8 (2C), 128.0 (3C), 127.6 (2C), 126.6, 126.5, 126.4, 121.9, 121.4, 120.7 (2C), 120.0 (q, 1JCF = 255.5 Hz), 118.8, 111.1, 109.3, 45.6; HRMS calc'd for C27H19F3N2O2Na (M+Na)+: 499.1240, found 499.1232</p><!><p>According to the method A, starting from 2-(2-naphthyl)-1H-indole (3aaf) and 3,4-dimethyl(2-nitrovinyl)benzene (2k): 70%; According to the method B, starting from phenylhydrazine (4aa), 2-acetylnaphthalene (5f) and 3,4-dimethyl(2-nitrovinyl)benzene (2k): 59%; m.p. = 144–147 °C (toluene/petroleum ether). 1H NMR (400 MHz, DMSO) δ, ppm: 11.43 (br. s, 1H), 10.73 (br. s, 1H), 8.81 (br. s, 1H), 8.03-7.97 (m, 3H), 7.92-7.90 (m, 1H), 7.77 (d, J = 8.2 Hz, 1H), 7.65 (dd, J = 8.7, 1.6 Hz, 1H), 7.60-7.54 (m, 2H), 7.38 (d, J = 8.0 Hz, 1H), 7.10-7.06 (m, 1H), 7.02-7.01 (m, 2H), 6.94-6.89 (m, 2H), 5.11 (s, 1H), 2.15 (s, 3H), 2.13 (s, 3H);); 13C NMR (100 MHz, DMSO) δ, ppm: 168.8, 138.1, 136.4, 136.0, 135.5, 133.9, 132.8, 132.2, 130.1, 129.1 (2C), 128.1, 128.0, 127.9, 127.6, 127.5, 126.7, 126.5, 126.3, 125.5, 122.4, 121.3, 118.5, 110.9, 110.1, 45.9, 19.6, 18.9; Calc'd for C28H24N2O2: C 79.98, H 5.75, N 6.66. Found: C 80.09, H 5.69, N 6.69; HRMS calc'd for C28H24N2O2Na (M+Na)+: 443.1730, found 443.1732.</p><!><p>According to the method A, starting from 2-(2-naphthyl)-1H-indole (3aaf) and 2-bromo(2-nitrovinyl)benzene (2d): 57%; According to the method B, starting from phenylhydrazine (4aa), 2-acetylnaphthalene (5f) and 2-bromo(2-nitrovinyl)benzene (2d): 55%; m.p. = 134–135 °C (toluene/petroleum ether). 1H NMR (400 MHz, CDCl3) δ, ppm: 8.45 (br. s, 1H), 7.88-7.86 (m, 3H), 7.71 (s, 1H), 7.59 (d, J = 7.7 Hz, 2H), 7.55-7.50 (m, 3H), 7.45 (d, J = 8.4 Hz, 1H), 7.41 (d, J = 8.1 Hz, 1H), 7.22-7.17 (m, 2H), 7. 13 (ddd, J = 7.9, 7.6, 0.1 Hz, 1H), 7.08 (t, J = 7.6 Hz, 1H), 5.65 (s, 1H); 13C NMR (100 MHz, CDCl3) δ, ppm: 169.8, 137.7, 137.6, 136.3, 133.5, 133.4, 133.1, 131.1, 129.4, 129.1, 129.0, 128.5, 128.0, 127.9, 127.8, 127.7, 126.9, 126.8, 125.6, 125.3, 123.0, 121.1, 120.3, 111.4, 108.0, 48.1; HRMS calc'd for C24H21BrN2O2Na (M+Na)+: 471.0679, found 471.0692.</p><!><p>According to the method A, starting from 2-(2-naphthyl)-1H-indole (3aaf) and 4-ethoxy(2-nitrovinyl)benzene (2l): 81%; According to the method B, starting from phenylhydrazine (4aa), 2-acetylnaphthalene (5f) and 4-ethoxy(2-nitrovinyl)benzene (2l): 72%; m.p. = 157–161 °C (toluene/petroleum ether). 1H NMR (400 MHz, CDCl3) δ, ppm: 8.36 (br. s, 1H), 8.35 (br. s, 1H),7.86-7.77 (m, 4H), 7.55-7.49 (m, 4H), 7.39 (t, J = 3.9 Hz, 1H), 7.22 (d, J = 8.8 Hz, 2H), 7.16 (dd, J = 7.4, 7.6 Hz, 1H), 7.04 (dd, J = 7.5, 7.6 Hz, 1H), 6.81 (d, J = 8.6 Hz, 2H), 5.29 (s, 1H), 3.99 (q, J = 7.0 Hz, 2H), 1.40 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ, ppm: 170.8, 158.3, 137.1, 136.3 (2C), 133.4, 133.0, 130.0 (2C) 129.4, 128.9, 128.3, 127.9 (2C) 127.6, 126.9, 126.8, 126.0, 122.9, 120.8, 120.7, 114.9 (2C), 111.3, 109.7, 63.6, 47.0, 15.0; EA: Calcd for C28H24N2O3: C 77.04, H 5.54, N 6.42. Found: C 77.23, H 5.48, N 6.32; HRMS calc'd for C28H24N2O3Na (M+Na)+: 459.1679, found 459.1673.</p><!><p>According to the method A, starting from 2-(2-naphthyl)-1H-indole (3aaf) and 4-methyl(2-nitrovinyl)benzene (2m): 80%; According to the method B, starting from phenylhydrazine (4aa), 2-acetylnaphthalene (5f) and 4-methyl(2-nitrovinyl)benzene (2m): 72%; m.p. = 135–140 °C (toluene/petroleum ether). 1H NMR (400 MHz, DMSO) δ, ppm: 11.46 (br. s, 1H), 10.79 (br. s, 1H), 8.85 (br. s, 1H), 8.03-7.90 (m, 4H), 7.76 (d, J = 8.1 Hz, 1H), 7.67 (dd, J = 8.6, 1.4 Hz, 1H), 7.59-7.54 (m, 2H), 7.39-7.36 (m, 2H), 7.29-7.17 (m, 3H), 7.08 (ddd, J = 7.5, 7.5, 1.0 Hz, 1H), 6.9 (ddd, J = 7.5, 7.5, 0.8 Hz,1H), 5.19 (s, 1H), 2.44 (s, 3H); 13C NMR (100 MHz, DMSO) δ, ppm: 168.6, 140.8, 136.4, 136.1, 132.8, 132.2, 130.0 (2C), 128.1 (2C), 128.0 (3C), 127.9, 127.6, 127.5, 126.6, 126.5, 126.3, 126.2, 122.3, 121.3, 118.6, 111.0, 109.9, 46.2, 35.8; Calc'd for C27H22N2O2: C 79.78, H 5.46, N 6.89. Found: C 79.91, H 5.40, N 6.94; HRMS calc'd for C27H22N2O2Na (M+Na)+: 429.1573, found 429.1703.</p><!><p>According to the method A, starting from 2-(2-naphthyl)-1H-indole (3aaf) and 3-methyl(2-nitrovinyl)benzene (2n): 76%; According to the method B, starting from phenylhydrazine (4aa), 2-acetylnaphthalene (5f) and 3-methyl(2-nitrovinyl)benzene (2n): 69%; m.p. = 155–156 °C (toluene/petroleum ether). 1H NMR (400 MHz, DMSO) δ, ppm: 11.45 (br. s, 1H), 10.76 (br. s, 1H), 8.83 (br. s, 1H), 8.02-7.89 (m, 4H), 7.76 (d, J = 8.6 Hz, 1H), 7.66 (dd, J = 8.5, 2.5 Hz, 1H), 7.59-7.54 (m, 2H), 7.39-7.37 (m, 2H), 7.30-7.06 (m, 3H), 7.03-6.98 (m, 1H), 6.93-6.89 (m, 1H), 5.15 (s, 1H), 2.22 (s, 3H); 13C NMR (100 MHz, DMSO) δ, ppm: 168.6, 140.7, 137.0, 136.4, 136.1, 132.8, 132.2, 130.1, 128.6, 128.1, 128.0, 127.9, 127.8, 127.6, 127.5, 126.9, 126.7, 126.5, 126.4, 125.2, 122.3, 121.3, 118.6, 111.0, 109.9, 108.3, 46.2; Calc'd for C27H22N2O2: C 79.78, H 5.46, N 6.89. Found: C 79.91, H 5.39, N 6.96; HRMS calc'd for C27H22N2O2Na (M+Na)+: 429.1573, found 429.1569.</p><!><p>According to the method A, starting from 2-(2-naphthyl)-1H-indole (3aaf) and 4-(N,N-diethylamino)(2-nitrovinyl)benzene (2o): 53%; According to the method B, starting from phenyl-hydrazine (4aa), 2-acetylnaphthalene (5f) and 4-(N,N-diethylamino)(2-nitrovinyl)benzene (2o): 50%; m.p. = 168–170 °C (chloroform). 1H NMR (400 MHz, DMSO) δ, ppm: 11.40 (br. s, 1H), 10.65 (br. s, 1H), 8.76 (br. s, 1H), 8.01 (d, J = 9.6 Hz, 2H), 7.98-7.90 (m, 2H), 7.85 (d, J = 8.1 Hz, 1H), 7.67 (dd, J = 8.5, 1.7 Hz, 1H), 7.59-7.53 (m, 2H), 7.36 (d, J = 8.1 Hz, 1H), 7.07 (ddd, J = 7.6, 7.1, 1.1 Hz, 1H), 7.02 (d, J = 8.8 Hz, 2H), 6.91 (ddd, J = 7.3, 7.1, 0.9 Hz, 1H), 6.55 (d, J = 8.9 Hz, 2H), 5.05 (s, 1H), 3.26 (q, J = 7.0 Hz, 4H), 1.03 (t, J = 7.0 Hz, 6H); 13C NMR (100 MHz, DMSO) δ, ppm: 169.3, 145.9, 136.4, 135.7, 132.9, 132.2, 130.3, 128.9 (2C), 128.1, 128.0 (2C), 127.6, 127.5, 127.1, 126.7, 126.5, 126.3, 122.7, 121.3, 118.5, 111.3 (2C), 110.9, 110.8, 45.4, 43.6 (2C), 12.4 (2C); Calc'd for C30H29N3O2: C 77.73, H 6.31, N 9.06. Found: C 77.85, H 6.27, N 8.99; HRMS calc'd for C30H29N3O2Na (M+Na)+: 486.2152, found 486.2159.</p><!><p>According to the method A, starting from 2-(2-naphthyl)-1H-indole (3aaf) and 4-(N,N-dimethylamino)(2-nitrovinyl)benzene (2p): 45%; According to the method B, starting from phenylhydrazine (4aa), 2-acetylnaphthalene (5f) and 4-(N,N-diethylamino)(2-nitrovinyl)benzene (2p): 43%; m.p. = 168–167 °C (toluene/petroleum ether). 1H NMR (400 MHz, DMSO) δ, ppm: 11.40 (br. s, 1H), 10.67 (br. s, 1H), 7.77 (br. s, 1H), 8.03-7.90 (m, 4H), 7.80 (d, J = 8.1 Hz, 1H), 7.67 (dd, J = 8.6, 1.6 Hz, 1H), 7.60-7.53 (m, 2H), 7.36 (d, J = 8.1 Hz, 1H), 7.09-7.04 (m, 3H), 6.9 (ddd, J = 8.1, 7.1, 1.0 Hz, 1H), 6.63 (dt, J = 8.9, 2.4 Hz, 2H), 5.07 (s, 1H), 2.82 (s, 6H); 13C NMR (100 MHz, DMSO) δ, ppm: 169.2, 149.0, 136.4, 135.8, 132.9, 132.2, 130.2, 128.6 (2C), 128.3, 128.2, 128.1, 128.0, 127.6, 127.4, 126.7, 126.5, 126.3, 122.7, 121.3, 118.5, 112.2 (2C), 110.9, 110.7, 45.4, 40.25 (2C); Calc'd for C28H25N3O2: C 77.22, H 5.79, N 9.65. Found: C 77.39, H 5.71, N 9.59; HRMS calc'd for C28H25N3O2Na (M+Na)+: 458.1839, found 458.1846.</p><!><p>According to the method A, starting from N-butyl-2-(2-naphthyl)-1H-indole (3caf) and (2-nitrovinyl)benzene (2a): 83%; m.p. = 110–112 °C (carbon tetrachloride). 1H NMR (400 MHz, DMSO) δ, ppm: 10.63 (br. s, 1H), 8.83 (br. s, 1H), 8.06-7.97 (m, 4H), 7.76 (d, J = 8.0 Hz, 1H), 7.63-7.59 (m, 2H), 7.49 (d, J = 8.2 Hz, 1H), 7.23-7.12 (m, 7H), 6.95 (t, J = 7.5 Hz, 1H), 4.77 (s, 1H), 4.05 (m, 2H), 1.49 (m, 2H), 1.02 (q, J = 7.37 Hz, 2H), 0.62 (t, J = 7.29 Hz, 3H); 13C NMR (100 MHz, DMSO) δ, ppm: 168.5, 140.7, 138.6, 136.3, 132.7, 132.6, 128.7, 128.0, 127.9 (4C), 127.8 (2C), 127.7, 126.7 (2C), 126.5 (2C), 126.12, 122.5, 121.3, 118.8, 111.1, 109.0, 46.3, 43.0, 31.5, 19.2, 13.4; HRMS calc'd for C30H28N2O2Na (M+Na)+: 471.2043, found 417.2054.</p><!><p>According to the method A, starting from N-(sec-butyl)-2-(2-naphthyl)-1H-indole (3daf) and (2-nitrovinyl)benzene (2a): 80%; m.p. = 131–133 °C (carbon tetrachloride). 1H NMR (400 MHz, DMSO) δ, ppm: 10.64 (br. s, 1H), 8.83 (br. s, 1H), 8.09-7.88 (m, 4H), 7.54 (d, J = 8.0 Hz, 1H), 7.62-7.56 (m, 2H), 7.51 (d, J = 8.3 Hz, 1H), 7.53-7.11 (m, 7H), 6.94 (t, J = 7.6 Hz, 1H), 4.77 (s, 1H), 3.99-3.90 (m, 2H), 1.88-1.87 (m, 1H),0.56-0.54 (m, 6H); 13C NMR (100 MHz, CDCl3) δ, ppm: 168.6, 140.7, 138.8, 136.7, 132.7, 132.5, 128.8, 128.0, 127.9 (4C), 127.8 (2C), 127.7, 126.7, 126.6, 126.5, 126.1, 122.4, 121.2 (2C), 118.7, 111.2, 110.3, 50.5, 46.3, 28.4, 19.8 (2C); HRMS calc'd for C30H28N2O2Na (M+Na)+: 471.2043, found 417.2048.</p><!><p>According to the method A, starting from N-butyl-2-(2-naphthyl)-1H-indole (3caf) and 4-isopropyl(2-nitrovinyl)benzene (2e): 68%; m.p. = 132–134 °C (carbon tetrachloride). 1H NMR (400 MHz, DMSO) δ, ppm: 10.60 (br. s, 1H), 8.05-7.94 (m, 4H), 7.81 (d, J = 8.0 Hz, 1H), 7.62-7.58 (m, 2H), 7.48 (d, J = 8.2 Hz, 2H), 7.14 (t, J = 7.3 Hz, 1H), 7.08-7.02 (m, 4H), 6.96 (t, J = 7.5 Hz, 1H), 4.74 (s, 1H), 4.04-4.03 (m, 2H), 2.82-2.74 (m, 1H), 1.52-1.45 (m, 2H), 1.12 (d, J = 6.9 Hz, 6H), 1.02 (q, J = 7.38 Hz, 2H), 0.62 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz, DMSO) δ, ppm: 168.7, 146.0, 138.5, 138.0, 136.3, 132.7, 132.5, 130.0, 128.7, 128.3, 128.1, 128.0, 127.8 (2C), 127.7, 126.7 (2C), 126.5, 125.8 (2C), 122.5, 121.2, 118.7, 111.3, 109.8, 46.0, 43.0, 32.9, 31.5, 23.8 (2C), 19.2, 13.4; HRMS calc'd for C33H34N2O2Na (M+Na)+: 513.2512, found 513.2521.</p><!><p>According to the method A, starting from N-benzyl-2-(2-naphthyl)-1H-indole (3eaf) and (2-nitrovinyl)benzene (2a): 75%; m.p. = 118–120 °C (carbon tetrachloride). 1H NMR (400 MHz, DMSO) δ, ppm: 10.68 (br.s, 1H), 8.86 (br. s, 1H), 7.99-7.87 (m, 4H), 7.77 (d, 1H), 7.43-7.34 (m, 3H), 7.26-7.15 (m, 8H), 7.08 (t, 1H), 6.95 (t, 1H), 6.85 (d, 1H), 5.32 (m, 2H), 4.83 (s, 1H); 13C NMR (100 MHz, DMSO) δ, ppm: 168.5, 140.6, 138.9, 138.2, 136.6, 132.6 (2C), 128.4 (2C), 128.0 (4C), 127.8 (2C), 127.7, 127.0, 126.9, 126.8, 126.6, 126.2, 126.0 (3C), 122.6, 121.6, 119.2, 111.7, 110.3, 46.8, 46.4; HRMS calc'd for C33H26N2O2Na (M+Na)+: 505.1883, found 505.1886.</p><!><p>A solution of 3aaaa (390 mg, 0.99 mmol) and PCl3 (140 mg, 1.02 mmol) in EtOAc is refluxed for 2 h. After the reaction mixture is allowed to cool down to rt, it is washed with NaHCO3 (15 mL) and water (2×15 mL). The solvent is then removed on the rotary evaporator and the residue is recrystallized from toluene to afford 266 mg (0.74 mmol, 75%) of nitrile 6. m.p. = 146–147 °C (toluene); 1H NMR (400 MHz, DMSO) δ, ppm: 11.85 (br.s, 1H), 8.09-7.94 (m, 4H), 7.7 (dd, J = 8.5, 1.8 Hz, 1H) 7.61-7.57 (m, 2H), 7.49 (d, J = 8.1 Hz, 1H), 7.45 (d, J = 8.0 Hz, 1H), 7.39-7.29 (m, 5H), 7.19 (ddd, J = 8.1, 7.1, 1.07 Hz, 1H), 7.05 (ddd, J = 8.0, 7.1, 0.9 Hz, 1H), 6.08 (s, 1H); 13C NMR (100 MHz, DMSO) δ, ppm: 136.6, 136.4, 136.3, 132.8, 132.5, 129.0 (2C), 128.8, 128.6, 128.2, 127.7, 127.5, 126.8 (5C), 126.4, 126.1, 122.3, 120.0, 119.8, 118.8, 111.9, 105.0, 32.7; HRMS calc'd for C26H18N2Na (M+Na)+: 381.1362, found 381.1362.</p><!><p>A solution of nitrile 6 (360 mg, 1.00 mmol) is stirred in 80% PPA (3 g) for 1 h at 80 °C. The reaction mixture is then allowed to cool down to rt, poured in water (15 mL) and neutralized with NH4OH. The obtained precipitate is collected by filtration and recrystallized from EtOAc to yield 369 mg (0.98 mmol, 98%) of amide 7. m.p. = 333–335 °C (EtOAc); 1H NMR (400 MHz, DMSO) δ, ppm: 11.49 (br. s., 1H), 8.03-7.87 (m, 4H), 7.69 (dd, J = 8.6, 1.3 Hz, 1H), 7.62 (d, J = 8.1 Hz, 1H), 7.63-7.59 (m, 2H), 7.41-7.36 (m, 2H), 7.29-7.16 (m, 5H), 7.09 (t, J = 7.8 Hz, 1H), 6.91 (t, 7.3 Hz, 1H), 5.28 (s, 1H); 13C NMR (100 MHz, DMSO) δ, ppm: 173.6, 141.2, 136.5, 136.1, 132.8, 132.2, 130.1, 128.5 (2C), 128.1 (3C), 127.9, 127.7, 127.4 (3C), 126.6, 126.4, 126.2, 121.5, 121.4, 118.8, 111.2, 110.4, 49.1; HRMS calc'd for C26H20N2ONa (M+Na)+: 399.1468, found 399.1478.</p><!><p>Human cancer cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA), the European Collection of Cell Culture (ECACC, Salisbury, UK) and the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany). Human cervical adenocarcinoma HeLa cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS). Human mammary carcinoma MCF-7 cells were cultured in RPMI supplemented with 10% FBS. The U87 cells (ATCC HTB-14) were cultured in DMEM culture medium, while the A549 cells (DSMZ ACC107) were cultured in RPMI culture medium supplemented with 10% heat-inactivated FBS. The glioblastoma multiforme Hs683 (ATCC HTB-138) and the T98G (ATCC CRL-1690) cell lines were cultivated in DMEM supplemented with 10% FBS. The Human uterine sarcoma MES-SA and MES-SA/Dx5 cells were cultured in RPMI-1640 medium supplemented with 10% FBS with MES SA/Dx5 maintained in the presence of 500 nM Doxorubicin (Sigma). SKMEL-28 cells (ATCC HTB72) and U373 glioblastoma cells (ECACC 08061901) were cultured in RPMI culture medium supplemented with 10% heat-inactivated FBS. Cell culture media were supplemented with 4 mM glutamine (Lonza code BE17-605E), 100 μg/mL gentamicin (Lonza code 17-5182), and penicillin-streptomycin (200 units/ml and 200 μg/ml) (Lonza code 17-602E). Neurosphere culture GBM 031810 was established using known methods47 and maintained in Neurobasal medium (Invitrogen Carlsbad, CA) with B27 supplement (20ul/ml; Invitrogen), Glutamax (10ul/ml; Invitrogen), fibroblast growth factor-2 (20 ng/ml; Peprotech, Rocky Hill, NJ, USA), epidermal growth factor (20 ng/ml; Peprotech), heparin (32 IE/ml; Sigma Aldrich, St. Louis, MO), and penicillin-streptomycin (1X, Invitrogen). Growth factors and heparin were renewed twice weekly. NHDF (code CC-2509) and NHLF (code CC-2512) cells lines were purchased from Lonza and were cultivated in FGM™-2 BulletKit™ culture medium (Lonza). All cell lines were cultured in T25 flasks, maintained and grown at 37° C, 95% humidity, 5% CO2.</p><!><p>Antiproliferative properties of the synthesized compounds were evaluated by MTT assay was used. All compounds were dissolved in DMSO at a concentration of either 100 mM or 50 mM prior to cell treatment. The cells were trypsinized and seeded at 4 × 103 cells per well into 96-well plates. The cells were grown for 24 h, treated with compounds at concentrations ranging from 0.001 to 100 μM and incubated for 48 h in 200 μL media. 20 μL of MTT reagent in serum free medium (5 mg/mL) was added to each well and incubated further for 2 h. Media was removed and the resulting formazan crystals were re-solubilized in 200 μL of DMSO. A490 was measured using a Molecular Devices Thermomax plate reader. The experiments were performed in quadruplicate and repeated at least twice for each compound per cell line. Cells treated with 0.1% DMSO were used as a negative control; 1 μM phenyl arsine oxide (PAO) was used as a positive control.</p><!><p>Selection of Doxorubicin Resistant Cells. Selection of the MES-SA/Dx5 cell line was done according to Harker et al.48 The cells were split and allowed to adhere overnight. The next day cells were initially exposed to a DOX concentration of 100 nM, which represented the GI50 concentration. The cells were maintained at this DOX concentration until their growth rate reached that of the untreated cells. The DOX concentration was then increased in two-fold increments following the same growth criteria at each concentration to a final DOX concentration of 500 nM. Each new DOX concentration required approximately 2 passages to reach the growth rate of the untreated cells.</p><!><p>The effects of 3aafa on the viability of human U373 glioblastoma and SKMEL melanoma cells were characterized in vitro using computer-assisted phase contrast video microscopy, as described elsewhere.49</p><!><p>U87 cells were plated at a density of 5 × 104 cells per well in 24-well plate in DMEM supplemented with 10% FBS. The following day, the cells in each well were re-fed with 1 mL of fresh DMEM/10% FBS, and treated with 3aafa to a final concentration between 15 and 5 μM. Cells were placed into the CO2 incubator and media not replaced for the duration of the experiment.</p><!><p>The log P values were determined theoretically using three different programs and the data was then used to find the mean log P and standard deviation. These programs included ChemAxon's Marvin sketch50,51 the Molinspiration software52 and VCCLAB's ALOGPS software.53,54</p>